BMS-986460 for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called BMS-986460, an experimental drug for men with metastatic castration-resistant prostate cancer. This type of cancer continues to grow despite hormone therapy. The trial's main goal is to determine the treatment's safety and effectiveness. It suits those diagnosed with prostate cancer that has spread and who have not responded to standard hormone treatments. Participants should not have brain metastases or serious heart problems. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Do I need to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that BMS-986460 is likely to be safe for humans?
Research has shown that BMS-986460 is in the early stages of testing with people. Scientists are primarily assessing its safety and how well the body tolerates it. Due to its early testing phase, limited information exists on how this treatment affects people.
In early studies like this, only a few participants initially receive the treatment. Scientists closely monitor for any adverse reactions or side effects. As a new treatment, its tolerability and potential side effects remain uncertain.
Prospective trial participants should discuss with the study team. They can provide more details on what to expect and address any safety concerns.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for prostate cancer, such as hormone therapy, chemotherapy, or radiation, BMS-986460 offers a unique approach by potentially targeting specific pathways involved in cancer growth with a novel mechanism of action. Researchers are excited about BMS-986460 because it represents a new class of drugs that could provide an alternative when existing options may not be effective or suitable. This treatment could offer new hope for patients by addressing prostate cancer in a way that current therapies do not, potentially leading to better outcomes with different side effect profiles.
What evidence suggests that BMS-986460 might be an effective treatment for prostate cancer?
Research shows that BMS-986460, the investigational treatment studied in this trial, might help treat a type of prostate cancer that has spread and resists usual hormone treatments. This drug targets specific processes that aid cancer cell survival and growth. Early studies suggest that BMS-986460 could shrink tumors and slow cancer progression. Although extensive data is not yet available, initial results are promising and suggest potential effectiveness for this challenging cancer.25678
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for men with advanced prostate cancer that has spread and doesn't respond to hormone therapy. They should be relatively healthy, able to perform daily activities (ECOG 0-1), and have a PSA level of at least 2 ng/mL. Men can't join if they have serious health issues, brain metastases, or significant heart disease.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986460 to assess safety, tolerability, and preliminary efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- BMS-986460
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania